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What is ECMO?
• An intervention that provides intense 
cardiopulmonary support
• Advantages of use in COVID-19 
patients
– Direct pulmonary artery flow improves 
oxygenation and ventilation
– Early mobility after removal
– Minimal cannula-associated 
complications or revisions
– Support of right side of heart in case 
of right ventricular dysfunction
ECMO Throughout the 
COVID-19 Pandemic
• Early data suggested a possible mortality
rate >90%
• Currently 3,041 COVID-19 confirmed 
patients have been treated with ECMO
• Independent risk factors
– Age, immunocompromised state, chronic 
respiratory disease, pre-ECMO cardiac 
arrest, degree of hypoxemia
• 3 categories for guidelines
– Recommended: technique/intervention is 
beneficial
– Not recommended: technique/intervention 
is not beneficial or harmful




– Are the correct criteria being implemented for the screening of 
ECMO patients based on resources during COVID-19?
• Hypothesis
– An increase in accepted COVID-19 ECMO referrals via changes to 
screening protocols allows for increased treatment and improved
outcomes.
• Objectives
– Evaluate screening criteria for ECMO patients during COVID-19
– Determine if there is fair evaluation of the medically ill without bias
– Potential liberalization of screening criteria
Approach
• Population: ECMO referrals between March-October 2020
• Outcomes
– Accepted or decline referral
– Patient disposition
– Survival length
• Contacting the referring physician
– Inquire about patient status before referral
– Process of referring patients
– Possible referral to another hospital if declined
• Analysis of accepted and declined patients within established window
– Survival or death
– Hospitalization duration and ECMO treatment duration
– Reason for declination
Results
Figure 1. Overall Patient Classification











Table 1. Mortality of Classified Patients within 30 days
Patient 
Classification Alive <30 days Deceased <30 days Deceased >30 days
Accepted 13 11 1
Declined 10 23 0
• Further separation of patient population allows for identification of 
possible missed patients
• Severe organ dysfunction, underlying co-morbidities, and previous 
mechanical ventilation limited acceptable patients
Results
• 9 of the surviving patient group were discharged in 
fair-good disposition
• Majority of admitted patients were placed on VV-
ECMO (63%)
• Mean age
– Declined patients = 47
– Accepted patients = 56
• Strongest predictors of mortality
– Age, chronic respiratory disease, VA-ECMO use, ECMO 
duration, acute kidney injury
Conclusions
• ECMO is a useful intervention for increasing the survival rate of 
COVID-19 patients
– Reserved for refractory cases of respiratory distress
• Current post-ECMO patient outcomes match the national 
average
• Expansion of criteria to allow earlier ECMO implementation can
improve patient mortality
• Continued use of ECMO for accepted patients will decrease 
mortality of ARDS due to COVID-19
• A major limitation was the collection of information on declined 
patients
Future Directions
• Long-term outcomes of patients surviving 
ECMO support
– Related to age, ECMO duration, initial disposition
• Racial disparities and equitable selection of 
ECMO patients
• Use of ECMO earlier in treatment course for 
patients with COVID-19
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